|
Global Sinusitis Pipeline Monitor 2020: Major Drugs, Companies and Developments
Thursday, August 6, 2020
DUBLIN, July 29, 2020 /PRNewswire/ -- The "Sinusitis Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
PIPELINE HIGHLIGHTS
Sinusitis is one of the widely researched conditions during 2020 with 20 companies actively focusing on realizing pipeline's potential. Development of Sinusitis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Sinusitis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Sinusitis.
Good progress is anticipated during 2020 and 2021 with Sinusitis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Sinusitis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
DRUG DEVELOPMENT PIPELINE OVERVIEW
The Sinusitis pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Sinusitis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Sinusitis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Sinusitis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
DRUG PROFILES
Sinusitis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:
-- Current Status of Development including phase advancements, regulatory
approvals of phases, acquisitions, licensing and technology transfers,
product launches in various markets, and others.
-- Phase of development
-- Mechanism of Action
-- Route of Administration
-- Companies involved including originator, licensing companies, developer,
investors, and others
-- New molecular entity details
-- Orphan drug designation and other special status provided by regulators
COMPANY PROFILES
Both small size and large size pharmaceutical companies are investing their resources in Sinusitis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Sinusitis. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 20 Sinusitis companies including company overview, key snapshot, contact information, and their strategies on accelerating Sinusitis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Reasons to Buy
-- The current market conditions are forcing companies and investors
worldwide to prioritize their investments and accelerate pipeline
candidates only through careful quantitative assessment.
-- This research work assists decision makers in pharmaceutical companies
towards successful pipeline development through critically evaluated
pipeline data
-- Buyers can identify most promising drug candidates for treatment of
Sinusitis
-- It allows users to strengthen their pipeline through acquisitions,
licensing and collaborations
-- Users can estimate possible delays in the delivery of pipeline or launch
of new products
-- Stay ahead of competition through understanding their pipeline
progression, strategies and outlook
-- The report details all the pipeline candidates under investigation in
various stages of development from Phase I through to Phase III to
enable business development managers to understand the impact of new
launches.
-- Optimize your licensing and technology transfer strategies through
identification of prospect partners
Companies Analyzed
-- AnaptysBio Inc
-- Argenx SE
-- Armata Pharmaceuticals Inc
-- Blue Water Vaccines Inc
-- Fogangren Bio-Pharma Limited
-- GeneOne Life Science Inc
-- GlycoMira Therapeutics Inc
-- Gossamer Bio Inc
-- IVIEW Therapeutics Inc
-- Knopp Biosciences LLC
-- Kyowa Hakko Kirin Co Ltd
-- Lyra Therapeutics
-- Merck & Co Inc
-- Nota Laboratories LLC
-- OptiNose US Inc
-- Pfizer Inc
-- Precigen Inc
-- ProclaRx LLC
-- RAPT Therapeutics Inc
-- Sanotize
For more information about this report visit https://www.researchandmarkets.com/r/j3p24c
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-sinusitis-pipeline-monitor-2020-major-drugs-companies-and-developments-301102198.html
SOURCE Research and Markets
|
|
|
|
|
|
 |
Energy CX Rebrands; Launches Omnichannel Marketing Strategy | Apr 19, 2024
|
|
eCosmetics: The Intersection of Technology and Beauty | Apr 19, 2024
|
|
Drip Drop Distro Unveils New Website: Elevating the Online Shopping Experience for Wholesale Buyers | Apr 19, 2024
|
|
New Wireless Sniffer Captures Wi-Fi 7, Bluetooth, and 802.15.4 Traffic Simultaneously | Apr 19, 2024
|
|
CMES Robotics Unveils State-of-the-Art Customer Experience Center in Chicago | Apr 19, 2024
|
|
Sony Electronics Announces a Compact Wide-Angle FE 16-25mm F2.8 G Zoom Lens | Apr 19, 2024
|
|
Golf forth and prosper as Arcade1Up presents un-fore-gettable Golden Tee 3D 35th Anniversary Deluxe Arcade Machine | Apr 19, 2024
|
|
Dow Jones Smart Money, a Collection of Free-to-Read Personal Finance Content, Launches Today | Apr 19, 2024
|
|
OffSec Names Applied Technology Academy Exclusive Black Hat USA Training Partner | Apr 19, 2024
|
|
VIDIZMO Launches Facial Attribution for AI-Driven Classifications, Enabling Deeper Audience Insights | Apr 19, 2024
|
|
|
|
